UNLIMITED TURBO LONG - NOVO-NORDISK B | Real-time Euronext Paris 08:08:38 2024-06-24 EDT | ||
| 12.54 EUR | -2.03% |
|
| Current month | +15.17% | ||
| 1 month | +15.01% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-24 | 12.54 | -2.03% |
| 24-06-21 | 12.8 | -1.46% |
| 24-06-20 | 12.98 | +3.59% |
| 24-06-19 | 12.54 | +0.48% |
| 24-06-18 | 12.48 | -0.87% |
Real-time Euronext Paris
Last update June 24, 2024 at 08:08 am
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| GH9LB | |
| ISIN | NLBNPNL2HAC1 |
| Date issued | 2023-08-24 |
| Strike | 534 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 3.63 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.07 € |
|---|---|
| Lowest since issue | 3.36 € |
| Spread | 0.01 € |
| Spread % | 0.08% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
987.9
DKK
Average target price
934.3
DKK
Spread / Average Target
-5.43%
- Stock Market
- Certificates
- GH9LB Certificat
